ライフサイエンスコーパス: levothyroxine

1 is thyroid hormone replacement therapy with levothyroxine.

2 identify precisely the timing and amount of levothyroxine adjustment required during pregnancy.

3 Compared with levothyroxine alone, treatment of primary hypothyroidism

4 oral bexarotene 400 mg/m2/d plus concomitant levothyroxine and a lipid-lowering agent.

5 ould inhibit the formation of (131)I-labeled levothyroxine and triiodothyronine and thereby reduce th

6 profiling of an amino group containing drug (levothyroxine) and its metabolites in human plasma, base

7 tal of 368 patients were assigned to receive levothyroxine (at a starting dose of 50 mug daily, or 25

8 yrotropin levels should be monitored and the levothyroxine dose adjusted accordingly.

9 oidism, and can be managed by increasing the levothyroxine dose by 30% when pregnancy is confirmed.

10 hat women with hypothyroidism increase their levothyroxine dose by approximately 30 percent as soon a

11 en with hypothyroidism should increase their levothyroxine dose during pregnancy, biochemical hypothy

12 During gestation, an increase in levothyroxine dose is required in more than 50% of women

13 yroid function was assessed monthly, and the levothyroxine dose was adjusted to attain a normal thyro

14 An increase in the levothyroxine dose was necessary during 17 pregnancies.

15 ation therapy (n = 23), in which their usual levothyroxine dose was reduced by 50 micro g/d and subst

16 at least a 6-month history of treatment with levothyroxine for primary hypothyroidism.

17 , as compared with 3.63 mIU per liter in the levothyroxine group (P<0.001), at a median dose of 50 mu

18 an IQ score was 94 (95% CI, 91 to 95) in the levothyroxine group and 91 (95% CI, 89 to 93) in the pla

19 % confidence interval [CI], 94 to 99) in the levothyroxine group and 94 (95% CI, 92 to 96) in the pla

20 3 in the placebo group and 0.2+/-14.4 in the levothyroxine group; between-group difference, 0.0; 95%

21 thetic triiodothyronine, or liothyronine, to levothyroxine improves the symptoms of hypothyroidism de

22 ndex (BMI) of 28.5 but is otherwise healthy; levothyroxine is the only prescription medication she ta

23 reatment for patients with hypothyroidism is levothyroxine (L-T4) along with normalization of serum t

24 Adding supraphysiologic doses of levothyroxine (L-T4) to standard treatment for bipolar d

25 that T3 deficiency may be unavoidable during levothyroxine (LT4) therapy.

26 Patients received either their usual dose of levothyroxine (n = 23) or combination therapy (n = 23),

27 SU can improve in response to treatment with levothyroxine or other thyroid drugs (strong evidence).

28 ons, women were randomly assigned to receive levothyroxine or placebo.

29 screening group were assigned to 150 mug of levothyroxine per day.

30 t of primary hypothyroidism with combination levothyroxine plus liothyronine demonstrated no benefici

31 The 4 generic and brand-name levothyroxine preparations studied are different but are

32 sults are equally applicable to all existing levothyroxine preparations.

33 All patients received each of the 4 levothyroxine products for 6-week periods in the same do

34 We aimed to determine whether levothyroxine provided clinical benefits in older person

35 Levothyroxine provided no apparent benefits in older per

36 truction or removal, necessitating life-long levothyroxine replacement.

37 The mean levothyroxine requirement increased 47 percent during th

38 Levothyroxine requirements increase as early as the fift

39 hypothyroidism is diagnosed, treatment with levothyroxine should be started to achieve serum TSH con

40 and chemically euthyroid and were receiving levothyroxine sodium, 0.1 or 0.15 mg.

41 esuscitation, specifically administration of levothyroxine (T4) and methylprednisolone (steroid, i.e.

42 de thyroid hormone (triiodothyronine [T3] or levothyroxine [T4]), corticosteroids, antidiuretic hormo

43 The use of levothyroxine to treat subclinical hypothyroidism is con

44 It is unknown whether levothyroxine treatment of women who are identified as h

45 The median gestational age at the start of levothyroxine treatment was 13 weeks 3 days; treatment w

46 In addition, levothyroxine use was determined in age- and sex-matched

47 id function status, polysomnography results, levothyroxine use, and clinical signs and symptoms in 33

48 The dose of levothyroxine was increased to maintain the thyrotropin

49 No beneficial effects of levothyroxine were seen on secondary-outcome measures.

50 clear; although, treatment with low doses of levothyroxine, which is usually used to treat hypothyroi